Back to the article

HealthRX.com · Printable supplement log

MK-677 food, supplement and timing record to show a clinician

List every product you actually take alongside ibutamoren, with amounts, clock times and what you ate. It gives a clinician the facts in one place; it is not a spacing schedule, because no validated food or supplement interval exists.

Companion to “MK-677 With Food or Supplements: What Has Actually Been Tested” · healthrx.com/mk-677/food-supplement-interactions · Facts checked 2026-10-18

What you take, when, and with what

Write the exact label name and source for each product, including powders, capsules and drinks.

Date and clock timeProduct (exact label)AmountMeal or snack at the timeAnything you noticed

Combinations you use that have no direct human co-administration study

  • Arginine
  • GABA
  • Melatonin
  • Creatine
  • Berberine
  • Calcium products or high-calcium meals
  • Pre-workout or other sports blends
  • Other (name it)

Why there is no timing rule to follow

  • FDA's ibutamoren review found no additional human pharmacokinetic data beyond brief descriptions.[1]
  • FDA says food-effect studies are what inform how and when a drug should be taken with food; none was identified for ibutamoren.[2]
  • Bedtime dosing comes from a 7-day hormone study, not from a comparison of clock times.[3]
  • The controlled-diet trial fixed food at 18 kcal/kg per day for everyone, so it could not show a meal effect.[4]

Questions to bring

  1. Has anyone tested this exact product or formulation fed versus fasted?
  2. Do any of my supplements matter for my glucose, kidney or liver results?
  3. Which of these products would you want me to stop or not start, and why?
  4. How would we tell a supplement effect apart from a product-quality problem?
Sources for the facts on this sheet
  1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Evaluation of Ibutamoren Mesylate for Inclusion on the 503A Bulk Drug Substances List (FDA briefing document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024). Accessed 2026-10-18. https://www.fda.gov/media/182087/download
  2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Assessing the Effects of Food on Drugs in INDs and NDAs: Clinical Pharmacology Considerations (Guidance for Industry, May 2026, Revision 1). Accessed 2026-10-18. https://www.fda.gov/media/121313/download
  3. Copinschi G, Van Onderbergen A, L'Hermite-Baleriaux M, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab 1996. PMID 8768828. https://pubmed.ncbi.nlm.nih.gov/8768828/
  4. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab 1998. PMID 9467534. https://pubmed.ncbi.nlm.nih.gov/9467534/

This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.